What is the real value of CVRs?
In many cases, the real value of CVRs depends on a specific stock’s future performance. In certain instances, these rights are similar to options because an investor contractually maintains rights but is under no obligation to complete a sale of a particular security at a specified price within a predetermined period.
Where can I buy CVRs shares?
Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How does a CVR benefit shareholders of a company?
CVRs also benefit shareholders of an acquired company by offering them the option to gain additional shares of stock in the acquired company as long as the stock has not met the previously established target price during the period set by the CVR.
What is an example of a CVR?
For example, an acquired company's shareholders may receive a CVR that allows them to gain additional shares of a target company if that target company’s share price drops below a certain value by a predetermined date. CVRs related to a company’s stock are typically concerned with the price performance of the security.
How were Corindus Vascular Robotics' earnings last quarter?
Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) released its earnings results on Tuesday, August, 7th. The medical equipment provider reported (...
Who are Corindus Vascular Robotics' key executives?
Corindus Vascular Robotics' management team includes the following people: Mr. Mark J. Toland , CEO, Pres & Director (Age 49) Mr. David W. Long...
Who are some of Corindus Vascular Robotics' key competitors?
Some companies that are related to Corindus Vascular Robotics include Consort Medical plc (CSRT.L) (CSRT) , EKF Diagnostics (EKF) , Immunodiagno...
What other stocks do shareholders of Corindus Vascular Robotics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Corindus Vascular Robotics investors own include Amarin (A...
What is Corindus Vascular Robotics' stock symbol?
Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."
How do I buy shares of Corindus Vascular Robotics?
Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is Corindus Vascular Robotics' stock price today?
One share of CVRS stock can currently be purchased for approximately $4.27.
How much money does Corindus Vascular Robotics make?
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) has a market capitalization of $891.08 million.
How many employees does Corindus Vascular Robotics have?
Corindus Vascular Robotics employs 90 workers across the globe.
How much is stock compensation expense for 2020?
What is the net loss for the year 2021?
Total stock compensation expense for the three months and year ended December 31, 2020 was $1.2 million and $5.7 million, respectively, compared to $1.7 million and $7.3 million for the same periods in 2019. About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
How much cash did the company raise in 2021?
Total stock compensation expense for the three months ended March 31, 2021 was $1.2 million compared to $1.8 million for the same period in 2020.
What is the role of ITK in lymphoma?
The increase in cash of $23.7 million resulted from $32.0 million received on February 17, 2021 from the company’s follow-on equity offering with institutional investors, reduced by $8.3 million of cash used in the quarter ended March 31, 2021.
What is the CPI-006 antibody?
ITK, an enzyme, is expressed predominantly in T-cells and plays a role in T-cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function. Interference with ITK signaling can modulate immune responses to various antigens.
How much did the CPI decrease in 2020?
CPI-006 is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine.
What is CPI 818?
For the full year 2020, the decrease of $6.1 million was primarily due to lower outside costs for ciforadenant and CPI-818 and a decrease in personnel and related costs, partially offset by an increase in outside costs for CPI-006.
Key Data Points
The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas.
Environmental, Social, and Governance Rating
Primary metrics and data points about Corindus Vascular Robotics, Inc. (DE).
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Price Target and Consensus Rating
"A" score indicates excellent relative ESG performance and a high degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for CVRS and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
What is a CVR in stock?
MarketBeat users like Corindus Vascular Robotics stock less than the stock of other Medical companies. 63.69% of MarketBeat users gave Corindus Vascular Robotics an outperform vote while medical companies recieve an average of 67.44% outperform votes by MarketBeat users.
Why are CVRs so risky?
The New York Stock Exchange (NYSE) Listed Company Manual refers to CVRs as "unsecured obligations of the issuer." 1 An unsecured obligation, also known as unsecured debt, carries no collateral or backing by an underlying asset. Shareholders do not have a guaranteed right that the reward will be granted to them.
What is non-transferable CVR?
CVRs come with some risks. That's because their real value is not discernible when they are issued. The risk shareholders face remains unknown because these rights are based entirely on the anticipated price of the stock or some unforeseeable occurrence.
What is a CVR?
Non-transferable CVRs, on the other hand, apply only to current shareholders of the acquired company and are distributed at the time of the merger. Companies prefer non-transferable CVRs as transferable CVRs listed on an exchange require regulatory work and incur higher costs.
What happens when a CVR is issued?
CVRs are rights granted to the shareholders of a target company by the acquirer. These rights stipulate that a shareholder will receive certain benefits if a specific performance event is met in a specific time frame. The benefits typically include a monetary benefit, such as additional stock or a cash payout.
When did Safeway get its CVR?
When CVRs are issued, a portion of the acquirer's risk is transferred to the target company's shareholders. This could have an adverse effect on any existing shareholders, depending on the price paid to acquire the company.
What is contingent value right?
Common stock shareholders of Safeway received CVRs in May 2015 as a result of the merger of Safeway into a wholly-owned subsidiary of Albertsons Companies that year. They were issued in connection to the sale of Property Development Centers, Safeway's real estate subsidiary, back in 2014.
